Between October 2011 and July 2012, 50 patients with confirmed VSA who had >/= 1 angina episodes/week despite amlodipine therapy (5 mg/day) were randomly assigned to receive either cilostazol (up to 200 mg/day) or placebo for 4 weeks. All patients were given diaries to record the ...
Side effects include headache and tachycardia. View all Chemical Properties Colourless Needles Originator Otsuka (Japan) Uses antibacterial; LD50(iv) 280mg/kg(mouse) Uses A potent phosphodiesterase III A (PDE3A) inhibitor (IC50=0.2uM) and inhibitor of adenosine uptake. Has antimitogeni, ...
Potential additive antiplatelet effects Pharmacokinetic interaction unlikely Caution advised; monitor bleeding times during concurrent administration Danazol Possible increases in plasma cilostazol concentrations If used concomitantly, consider reduced cilostazol dosage (i.e., 50 mg twice daily) Diltiazem ...
Antivirals: concentration possibly increased by boceprevir, ritonavir and telaprevir - reduce cilostazol dose to 50 mg twice daily. Calcium-channel blockers: concentration increased by diltiazem - consider reducing cilostazol dose. Ulcer-healing drugs: concentration increased by omeprazole - consider reducin...
Further, a weight of the cilostazol is 50 to 100 mg, and a weight of the extract of ginkgo biloba is 40 to 80 mg in the anti-thrombotic pharmaceutical composition.RYU, KEUN HOJEON, SUN DUCKHAN, HYE YOUNGLEE, SO YOUNGLEE, GUANG SEOK...
dilatation, but its efficacy in patients with VSA is unknown.Between October 2011 and July 2012, 50 patients with confirmed VSA who had ≥1 angina episodes/week despite amlodipine therapy (5mg/day) were randomly assigned to receive either cilostazol (up to 200mg/day) or placebo for 4weeks. ...
Cisplatin (cis-diammine-dichloroplatinum; CDDP) is an anticancer drug that induces significant hearing loss and balance dysfunction as side effects. Cilostazol (CS, 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl) butoxy]-3, 4-dihydro-2-(1H)-quinolinone) has neuropr
A total of 267 patients (73.6%) had hypertension; few had large artery atheroma (carotid stenosis ≥50%: 9 [2.9%]) or embolic sources (atrial fibrillation: 5 [1.4%]).13,20 The median time between stroke and randomization was 79 (IQR, 27.0-244.0) days. In terms of baseline brain ...
Soga24 2017 RCT 100 EVT 50 (50.0) 73 ± 10 74.00 200 mg/d None Aspirin (100 mg/d) Periprocedural 3 Ishii25 2010 Retrospective cohort 26 EVT 174 (37.2) 66 ± 11 59.20 200 mg/d None Aspirin (100 mg/d) Periprocedural 37 Neel8 2015 Retrospective cohort 51 EVT (37.47%), open (62.53...
Some third parties are outside of the European Economic Area, with varying standards of data protection. See our privacy policy for more information on the use of your personal data. Manage preferences for further information and to change your choices. Accept all cookies ...